Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
JJJason J LukePRPiotr RutkowskiPQPaola QueiroloMDMichele Del VecchioJMJacek Mackiewicz
The Maria Sklodowska-Curie National Research Institute of Oncology · Fondazione IRCCS Istituto Nazionale dei Tumori · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
468
total citations
- FWCI
- 45.03
- Percentile
- 100%
- References
- 19
Citations per year
Authors
28- JJJason J LukeCorresponding
- PRPiotr Rutkowski
The Maria Sklodowska-Curie National Research Institute of Oncology
- PQPaola Queirolo
- MDMichele Del Vecchio
Fondazione IRCCS Istituto Nazionale dei Tumori
- JMJacek Mackiewicz
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Placebo
- Adjuvant therapy
- Melanoma
- Adjuvant
- Phases of clinical research
No related works found for this paper.